



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

May 30, 2017

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

For NATCO Pharma Limited

A handwritten signature in black ink that reads "M. Adinarayana".

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/03/2017

Press Release

Hyderabad, 30th May, 2017

NATCO records INR 2078.9 Crore total consolidated revenue and INR 486.0 Crore of profit, after tax, for the full year ended March 2017

Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR **2078.9** Crore for the year ended on 31st March, 2017, as against INR 1089.7 Crore for the last year, reflecting an year-over-year growth of **90.8%**. The net profit for the period, on a consolidated basis, was INR **486.0** Crore, as against INR 157.1 Crore last year, showing a growth of **209.3%**.

For the fourth quarter (Q4) ended March 31st, 2017, the company recorded a net revenue of INR 577.2 Crore, on a consolidated basis, as against INR 394.8 Crore during Q4, FY 2016, posting an increase of 46.2%. The profit after tax, on a consolidated basis, was recorded as INR 176.7 Crore for the quarter, as against INR 62.8 Crore same quarter last year, showing a growth of 181.4%.

The revenue and profit growth for the company during the financial year was driven primarily due to the sales of generic Oseltamivir product in the USA market and continued growth of domestic formulations business.

All results for the quarter and previous year FY2016 have been restated to comply with Indian Accounting Standards (Ind AS) to make them comparable.

Forwarded for favour of publication
For NATCO Pharma Limited

M. Adinarayana

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)